Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278163 | 0.93 | EGLN1 (0.57) | HTTSMN1; SMN2EGLN1LMNAKDM4E | |
| SCHEMBL619854 | 0.92 | HTT (0.52) | HTTSMN1; SMN2GALR3NR2F2SUCNR1 | |
| SCHEMBL619835 | 0.91 | HTT (0.49) | HTTSMN1; SMN2GALR3NR2F2SUCNR1 | |
| SCHEMBL619376 | 0.91 | LIPG (0.49) | HTTSMN1; SMN2GALR3NR2F2SUCNR1 | |
| SCHEMBL616897 | 0.89 | EGLN1 (0.60) | HTTSMN1; SMN2SUCNR1EGLN1LMNA | |
| SCHEMBL620070 | 0.89 | HTT (0.54) | HTTSMN1; SMN2GALR3NR2F2EGLN1 | |
| SCHEMBL619610 | 0.88 | HTT (0.48) | HTTSMN1; SMN2GALR3NR2F2SUCNR1 | |
| SCHEMBL619017 | 0.87 | HTT (0.69) | HTTSMN1; SMN2LMNARAB9AHPGD | |
| SCHEMBL618734 | 0.87 | EGLN1 (0.60) | HTTSMN1; SMN2EGLN1LMNAALDH1A1 | |
| SCHEMBL616709 | 0.87 | SMN1; SMN2 (0.54) | HTTSMN1; SMN2EGLN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | claimed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | claimed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | claimed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| EP-2023913-A2 | METHODS FOR TREATING BLOOD DISORDERS | Colorado State University Research Foundation (US) | 2009-02-18 | — | — | EP | claimed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | claimed |
| WO-2007133653-A2 | METHODS FOR TREATING BLOOD DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| WO-2007006544-A2 | CYCLIC ADENOSINE MONOPHOSPHATE COMPOUNDS FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2007-01-18 | — | — | WO | claimed |
| EP-1546164-A4 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG LIFE SCIENCES LTD (KR) | 2006-06-07 | — | — | EP | claimed |
| EP-1546164-A1 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG Life Sciences Ltd. (KR) | 2005-06-29 | — | — | EP | claimed |
| WO-2004029064-A1 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG LIFE SCIENCES LTD. (KR) | 2004-04-08 | — | — | WO | claimed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | claimed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | claimed |
| US-5908930-A | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors | PFIZER INC. (US) | 1999-06-01 | — | — | US | claimed |
| WO-1996028444-A1 | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1996-09-19 | — | — | WO | claimed |
| US-4650868-A | 7-deazapurine derivatives useful as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-17 | — | — | US | claimed |
| US-4138558-A | Anthraquinone compounds | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1979-02-06 | — | — | US | claimed |
| US-12011490-B2 | Dental photocurable composition excellent in operability and storage stability | SHOFU INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| US-3962215-A | PHOSPHORYLATION, ACYLATION, WATER, ACID CHLORIDE, ALCOHOL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
| US-3954732-A | BACTERICIDAL PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011490-B2 | Dental photocurable composition excellent in operability and storage stability | H1-0, CCND1, CCNT1 | HTT 932/4885SMN1; SMN2 1171/4885GALR3 2190/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | HTT 4219/4885SMN1; SMN2 4137/4885GALR3 246/4885 |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | HTT 551/4885SMN1; SMN2 1168/4885GALR3 2878/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | HTT 508/4885SMN1; SMN2 179/4885GALR3 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.